Symbols / CRDL $1.05 -0.94%
CRDL Chart
About
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 117.26M |
| Enterprise Value | 80.34M | Income | -34.78M | Sales | — |
| Book/sh | 0.08 | Cash/sh | 0.13 | Dividend Yield | — |
| Payout | 0.00% | Employees | 18 | IPO | — |
| P/E | — | Forward P/E | -3.96 | PEG | — |
| P/S | — | P/B | 13.19 | P/C | — |
| EV/EBITDA | -2.21 | EV/Sales | — | Quick Ratio | 3.59 |
| Current Ratio | 3.89 | Debt/Eq | 1.40 | LT Debt/Eq | — |
| EPS (ttm) | -0.30 | EPS next Y | -0.27 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 | ROA | -148.83% |
| ROE | -3.48% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 111.68M |
| Shs Float | 75.33M | Short Float | 2.07% | Short Ratio | 6.62 |
| Short Interest | — | 52W High | 1.59 | 52W Low | 0.77 |
| Beta | 0.73 | Avg Volume | 344.28K | Volume | 229.68K |
| Target Price | $7.47 | Recom | None | Prev Close | $1.06 |
| Price | $1.05 | Change | -0.94% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.46
Mean price target
2. Current target
$1.05
Latest analyst target
3. DCF / Fair value
$-2.47
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.05
Low
$4.97
High
$8.91
Mean
$7.46
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-12-01 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-06-02 | init | HC Wainwright & Co. | — → Buy | $9 |
| 2025-04-16 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-04-07 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-02-24 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-12-18 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-11-20 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-10-24 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-06-26 | init | Roth MKM | — → Buy | $10 |
| 2024-06-14 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-06-07 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-05-23 | main | Canaccord Genuity | Buy → Buy | $8 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-04-22 | init | HC Wainwright & Co. | — → Buy | $9 |
- (CRDL) Trading Advice (CRDL:CA) - Stock Traders Daily Sun, 15 Mar 2026 12
- Cardiol Therapeutics (NASDAQ: CRDL) outlines heart programs at TD Cowen - Stock Titan Wed, 25 Feb 2026 08
- Cardiol Therapeutics (NASDAQ:CRDL) Shares Down 1% - What's Next? - MarketBeat ue, 03 Mar 2026 08
- Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before Long - Yahoo Finance Mon, 12 Jan 2026 08
- Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million - TMX Newsfile Fri, 23 Jan 2026 08
- Cardiol Therapeutics (CRDL) Stock Analysis Report | Financials & Insights - Benzinga Japan hu, 05 Mar 2026 06
- CRDL Stock Rating Reiterated at 'Buy' by HC Wainwright & Co. | C - GuruFocus ue, 10 Feb 2026 08
- Heart drug developer Cardiol lines up $13.5M to fund trials and research - Stock Titan Fri, 16 Jan 2026 08
- H.C. Wainwright reaffirms Buy rating on Cardiol Therapeutics stock at $9 target - Investing.com ue, 02 Dec 2025 08
- Cardiol falls after mid-stage data for heart disease treatment - Seeking Alpha Wed, 06 Aug 2025 07
- Canadian Investment Regulatory Organization Trade Resumption - CRDL - Investing News Network Mon, 20 Oct 2025 07
- Cardiol Therapeutics (NASDAQ: CRDL) extends cash runway to Q3 2027 after $11.4M financing - Stock Titan ue, 21 Oct 2025 07
- Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million - TMX Newsfile Fri, 16 Jan 2026 08
- Cardiol Therapeutics (TSE:CRDL) Trading Down 4.8% - Time to Sell? - MarketBeat Sat, 28 Feb 2026 06
- (CRDL) Stock Analysis and Trading Signals (CRDL:CA) - Stock Traders Daily Wed, 22 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 100000 | 100000.0 | — | Acquisition carried out privately at price 1.00 per share. | Elsley (David) | Director of Issuer | — | 2025-10-17 00:00:00 | D |
| 1 | 50000 | 50000.0 | — | Acquisition carried out privately at price 1.00 per share. | Torreamione (Guilermo) | Senior Officer of Issuer | — | 2025-10-17 00:00:00 | D |
| 2 | 133334 | nan | — | — | Hamer (Andrew Warwick M.D.) | Senior Officer of Issuer | — | 2025-10-01 00:00:00 | D |
| 3 | 13334 | nan | — | — | Chao (Jennifer M) | Director of Issuer | — | 2025-09-08 00:00:00 | D |
| 4 | 70000 | nan | — | — | Hamer (Andrew Warwick M.D.) | Senior Officer of Issuer | — | 2025-09-08 00:00:00 | D |
| 5 | 13334 | nan | — | — | Loxam (Teri) | Director of Issuer | — | 2025-09-08 00:00:00 | D |
| 6 | — | nan | — | — | Garnett (Timothy John) | Director of Issuer | — | 2025-05-28 00:00:00 | D |
| 7 | 20000 | nan | — | — | Chao (Jennifer M) | Director of Issuer | — | 2025-04-08 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -42.28M | -29.01M | -50.12M | -45.25M |
| TotalUnusualItems | 2.38M | -530.99K | 9.00M | 6.81M |
| TotalUnusualItemsExcludingGoodwill | 2.38M | -530.99K | 9.00M | 6.81M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -36.68M | -28.13M | -30.93M | -31.64M |
| ReconciledDepreciation | 373.11K | 248.35K | 219.91K | 220.42K |
| EBITDA | -39.90M | -29.54M | -41.12M | -38.44M |
| EBIT | -40.28M | -29.79M | -41.34M | -38.66M |
| NetInterestIncome | 1.19M | 2.04M | 1.24M | 106.00K |
| InterestIncome | 1.19M | 2.04M | 1.24M | 106.00K |
| NormalizedIncome | -39.06M | -27.60M | -39.93M | -38.45M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -36.68M | -28.13M | -30.93M | -31.64M |
| TotalExpenses | 40.28M | 29.79M | 41.34M | 38.74M |
| DilutedAverageShares | 71.57M | 64.46M | 62.51M | 43.22M |
| BasicAverageShares | 71.57M | 64.46M | 62.51M | 43.22M |
| DilutedEPS | -0.51 | -0.44 | -0.49 | -0.73 |
| BasicEPS | -0.51 | -0.44 | -0.49 | -0.73 |
| DilutedNIAvailtoComStockholders | -36.68M | -28.13M | -30.93M | -31.64M |
| NetIncomeCommonStockholders | -36.68M | -28.13M | -30.93M | -31.64M |
| NetIncome | -36.68M | -28.13M | -30.93M | -31.64M |
| NetIncomeIncludingNoncontrollingInterests | -36.68M | -28.13M | -30.93M | -31.64M |
| NetIncomeContinuousOperations | -36.68M | -28.13M | -30.93M | -31.64M |
| PretaxIncome | -36.68M | -28.13M | -30.93M | -31.64M |
| OtherIncomeExpense | 2.41M | -381.25K | 9.17M | 6.92M |
| OtherNonOperatingIncomeExpenses | 28.22K | 149.74K | 164.44K | 112.23K |
| GainOnSaleOfSecurity | 2.38M | -530.99K | 9.00M | 6.81M |
| NetNonOperatingInterestIncomeExpense | 1.19M | 2.04M | 1.24M | 106.00K |
| InterestIncomeNonOperating | 1.19M | 2.04M | 1.24M | 106.00K |
| OperatingIncome | -40.28M | -29.79M | -41.34M | -38.66M |
| OperatingExpense | 40.28M | 29.79M | 41.34M | 38.74M |
| ResearchAndDevelopment | 14.01M | 14.22M | 18.96M | 10.87M |
| SellingGeneralAndAdministration | 26.26M | 15.56M | 22.37M | 27.87M |
| GeneralAndAdministrativeExpense | 26.26M | 15.56M | 22.37M | 27.87M |
| OtherGandA | 26.26M | 15.56M | 22.37M | 27.87M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 78.76K |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 78.76K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 82.61M | 65.35M | 64.04M | 61.92M |
| ShareIssued | 82.61M | 65.35M | 64.04M | 61.92M |
| TotalDebt | 158.53K | 174.34K | 72.87K | 117.58K |
| TangibleBookValue | 24.73M | 28.04M | 51.91M | 75.86M |
| InvestedCapital | 24.73M | 28.25M | 52.20M | 76.24M |
| WorkingCapital | 24.66M | 27.86M | 51.63M | 75.58M |
| NetTangibleAssets | 24.73M | 28.04M | 51.91M | 75.86M |
| CapitalLeaseObligations | 158.53K | 174.34K | 72.87K | 117.58K |
| CommonStockEquity | 24.73M | 28.25M | 52.20M | 76.24M |
| TotalCapitalization | 24.73M | 28.25M | 52.20M | 76.24M |
| TotalEquityGrossMinorityInterest | 24.73M | 28.25M | 52.20M | 76.24M |
| StockholdersEquity | 24.73M | 28.25M | 52.20M | 76.24M |
| OtherEquityInterest | 3.52M | 3.52M | 4.18M | |
| RetainedEarnings | -179.25M | -142.58M | -114.45M | -83.52M |
| AdditionalPaidInCapital | 24.65M | 18.79M | 15.59M | 12.66M |
| CapitalStock | 179.34M | 148.52M | 147.55M | 142.92M |
| CommonStock | 179.34M | 148.52M | 147.55M | 142.92M |
| TotalLiabilitiesNetMinorityInterest | 7.14M | 8.45M | 9.83M | 11.64M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 125.52K | 158.53K | 22.42K | 72.87K |
| LongTermDebtAndCapitalLeaseObligation | 125.52K | 158.53K | 22.42K | 72.87K |
| LongTermCapitalLeaseObligation | 125.52K | 158.53K | 22.42K | 72.87K |
| CurrentLiabilities | 7.01M | 8.30M | 9.80M | 11.57M |
| OtherCurrentLiabilities | 238.18K | 419.90K | 6.66M | |
| CurrentDebtAndCapitalLeaseObligation | 33.01K | 15.81K | 50.45K | 44.71K |
| CurrentCapitalLeaseObligation | 33.01K | 15.81K | 50.45K | 44.71K |
| PayablesAndAccruedExpenses | 6.98M | 8.04M | 9.33M | 4.86M |
| TotalAssets | 31.86M | 36.70M | 62.03M | 87.88M |
| TotalNonCurrentAssets | 195.59K | 547.42K | 590.54K | 735.74K |
| GoodwillAndOtherIntangibleAssets | 0.00 | 210.36K | 294.80K | 379.25K |
| OtherIntangibleAssets | 210.36K | 294.80K | 379.25K | |
| NetPPE | 195.59K | 337.06K | 295.74K | 356.49K |
| AccumulatedDepreciation | -772.66K | -656.76K | -492.85K | -357.38K |
| GrossPPE | 968.25K | 993.82K | 788.59K | 713.88K |
| Leases | 237.25K | 237.25K | 237.25K | 237.25K |
| OtherProperties | 514.19K | 561.05K | 372.18K | 331.09K |
| MachineryFurnitureEquipment | 216.81K | 195.52K | 179.15K | 145.54K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 31.67M | 36.15M | 61.44M | 87.14M |
| PrepaidAssets | 726.51K | 941.44K | 1.49M | 2.83M |
| Receivables | 361.62K | 279.87K | 480.20K | 407.13K |
| OtherReceivables | 261.25K | 137.13K | 270.27K | 341.39K |
| AccountsReceivable | 100.37K | 142.75K | 209.92K | 65.74K |
| CashCashEquivalentsAndShortTermInvestments | 30.58M | 34.93M | 59.47M | 83.90M |
| CashAndCashEquivalents | 30.58M | 34.93M | 59.47M | 83.90M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -25.08M | -25.24M | -27.30M | -23.55M |
| RepaymentOfDebt | -41.53K | -55.38K | -53.93K | -51.92K |
| IssuanceOfCapitalStock | 21.36M | 0.00 | 0.00 | 84.08M |
| CapitalExpenditure | -21.29K | -64.31K | -74.71K | -12.92K |
| EndCashPosition | 30.58M | 34.93M | 59.47M | 83.90M |
| BeginningCashPosition | 34.93M | 59.47M | 83.90M | 14.03M |
| EffectOfExchangeRateChanges | 1.89M | 762.04K | 2.92M | -11.13K |
| ChangesInCash | -6.24M | -25.30M | -27.35M | 69.89M |
| FinancingCashFlow | 18.84M | -55.38K | -53.93K | 93.44M |
| CashFlowFromContinuingFinancingActivities | 18.84M | -55.38K | -53.93K | 93.44M |
| NetOtherFinancingCharges | -2.65M | -5.24M | ||
| ProceedsFromStockOptionExercised | 177.51K | 0.00 | 0.00 | 14.65M |
| NetCommonStockIssuance | 21.36M | 0.00 | 0.00 | 84.08M |
| CommonStockIssuance | 21.36M | 0.00 | 0.00 | 84.08M |
| NetIssuancePaymentsOfDebt | -41.53K | -55.38K | -53.93K | -51.92K |
| NetLongTermDebtIssuance | -41.53K | -55.38K | -53.93K | -51.92K |
| LongTermDebtPayments | -41.53K | -55.38K | -53.93K | -51.92K |
| InvestingCashFlow | -21.29K | -64.31K | -74.71K | -12.92K |
| CashFlowFromContinuingInvestingActivities | -21.29K | -64.31K | -74.71K | -12.92K |
| NetPPEPurchaseAndSale | -21.29K | -64.31K | -74.71K | -12.92K |
| PurchaseOfPPE | -21.29K | -64.31K | -74.71K | -12.92K |
| OperatingCashFlow | -25.06M | -25.18M | -27.22M | -23.54M |
| CashFlowFromContinuingOperatingActivities | -25.06M | -25.18M | -27.22M | -23.54M |
| ChangeInWorkingCapital | -931.57K | -545.88K | 5.75M | 76.52K |
| ChangeInPayablesAndAccruedExpense | -1.06M | -1.29M | 4.47M | 2.39M |
| ChangeInPrepaidAssets | 214.93K | 546.47K | 1.35M | -2.15M |
| ChangeInInventory | 0.00 | 0.00 | 17.97K | |
| ChangeInReceivables | -81.75K | 200.32K | -73.07K | -187.20K |
| ChangesInAccountReceivables | 42.38K | 67.18K | -144.18K | -59.95K |
| OtherNonCashItems | 25.72K | 32.38K | 534.43K | 4.13M |
| StockBasedCompensation | 14.28M | 4.16M | 5.01M | 8.50M |
| DepreciationAmortizationDepletion | 373.11K | 248.35K | 219.91K | 220.42K |
| DepreciationAndAmortization | 373.11K | 248.35K | 219.91K | 220.42K |
| AmortizationCashFlow | 210.36K | 84.44K | 84.44K | 84.44K |
| AmortizationOfIntangibles | 210.36K | 84.44K | 84.44K | 84.44K |
| Depreciation | 162.76K | 163.91K | 135.46K | 135.98K |
| OperatingGainsLosses | -2.13M | -943.76K | -7.81M | -4.82M |
| GainLossOnInvestmentSecurities | -238.18K | -181.72K | -4.89M | -4.83M |
| NetForeignCurrencyExchangeGainLoss | -1.89M | -762.04K | -2.92M | 11.13K |
| NetIncomeFromContinuingOperations | -36.68M | -28.13M | -30.93M | -31.64M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for CRDL
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|